Skip to main content

Table 1 Clinicopathological characteristics of study patients

From: AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer

Patients (%)

186

(100.0)

Age at diagnosis [years]

 Median (range)

57

(26–85)

Progression-free survival [months]

 Median (range)

16

(1–48)

 Number of recurrencies (%)

106

(57.0)

Overall survival [months]

 Median (range)

24

(1–49)

 Number of deaths (%)

54

(29.0)

Histology (%)

 Serous

164

(88.2)

 Non-serous

22

(11.8)

FIGO (%)

 II

9

(4.8)

 III

148

(79.6)

 IV

29

(15.6)

Grading (%)

 1

6

(3.2)

 2

43

(23.1)

 3

137

(73.7)

Residual disease after initial surgery (%)

 None

132

(71.0)

  ≤ 1 cm

34

(18.3)

  > 1 cm

20

(10.8)

Type of chemotherapy (%, 30 missing [16.1 %])

 Adjuvant

124

(66.7)

 Neoadjuvant

15

(8.1)

 Intraperitoneal

17

(9.1)

Response to first-line chemotherapy (%, 1 missing)

 Responder

138

(74.2)

 Non-Responder

47

(25.3)